Evidence of measurable or evaluable non-measurable disease per RECIST, v.
Radiographically measurable or evaluable disease per RECIST v..
Measurable or non-measurable, but evaluable disease using RECIST v.
Cohort B Safety Run-In (Ribociclib + PDR + Fulvestrant): Evaluable or measurable disease by RECIST .
Patients must have measurable or evaluable disease per RECIST . criteria
PART I: participants are required to have only evaluable disease (disease that is visible on imaging studies but does not meet RECIST criteria for measurable disease)
One or more measurable or nonmeasurable evaluable lesions per RECIST ..
Patients must have measurable or evaluable disease as defined per the RECIST v. except patients with mCRPC.
Patients in the dose escalation phase of the study must have measurable or evaluable disease according to RECIST . criteria
Patients must have measurable or evaluable disease per RECIST . criteria
Measurable or evaluable disease by RECIST v.
Evaluable disease per RECIST .
Evaluable/measurable disease by RECIST
Radiologically measurable and clinically evaluable disease as per RECIST v.
Evaluable or measurable disease as defined by RECIST v. may be enrolled in the dose escalation part; for the dose confirmation part, subjects must have measurable disease by RECIST v. or biomarker for response.
Patient with a TPwt locally advanced or metastatic solid malignancy and with measurable or non-measurable (but evaluable) disease as determined by RECIST . criteria.
Patients must have measurable or evaluable advanced and/or metastatic disease by RECIST ..
Must have evaluable or measurable disease per RECIST .
Evaluable disease by RECIST v..
Histologically confirmed advanced refractory solid tumor that is measurable or evaluable per RECIST . criteria.
Patients must have measurable or non-measurable disease that is evaluable per RECIST .;
Phase : Participants must have either measurable or evaluable disease as per RECIST ..
Must be determined to have metastatic or unresectable disease, as determined by treating physician; (must have at least evaluable disease, but does not need to be measurable disease by RECIST .)
Evaluable or measurable disease based on RECIST . ()
Have measurable or evaluable disease based on RECIST .
Measurable and/or evaluable disease as per the RECIST criteria version (v) .
Evaluable disease: . During Part , evaluable disease is required; measurable disease per RECIST v. is recommended but not required, . Subjects enrolled in Part  must demonstrate measurable disease per the disease-specific criteria.
Measurable or evaluable disease by RECIST v. (not required for the cPoP study)
Radiographically measurable or evaluable disease per RECIST v..
Have evaluable disease by RECIST . and PCWG criteria
CA- only disease without RECIST . measurable or otherwise evaluable disease
Measurable disease by RECIST or evaluable disease (e.g., bone metastasis, or lesions which do not fulfill RECIST criteria for metastatic disease)
Has evaluable or measurable disease by RECIST v. criteria
At least one measurable/evaluable lesion by RECIST v.
Measurable or evaluable disease per RECIST v.
Patient has evaluable disease by RECIST v. (Appendix ).
Existence of measurable or evaluable disease (as per RECIST . criteria).
Measurable or evaluable disease according to RECIST v..
In Stage , evaluable disease per RECIST .. In Stage , measurable disease.
Must have baseline measurable or evaluable disease per RECIST
Have measurable and/or evaluable disease by RECIST .
Triple negative breast cancer patients: participants may have either measurable disease via RECIST . criteria or evaluable disease
Participants must have measurable disease that is evaluable as per RECIST v.
Subjects with solid tumors, with the exception of CRPC, must demonstrate measurable disease, per RECIST v.. NOTE: Subjects with NMC that do not meet the RECIST v. criteria for measurable disease, but have evaluable disease may be considered for enrollment after discussion with the GSK medical monitor..
Measurable disease via RECIST v. or non-measurable, evaluable disease with at least one evaluable bone lesion via RECIST v.
The subject has measurable disease or nonmeasurable, evaluable disease per RECIST .. (NOTE: pleural effusions, ascites or other third fluid space are not evaluable diseases per RECIST .).
Participants must have measurable disease by RECIST v. or non-measurable, evaluable disease with atleast one evaluable bone lesion by RECIST v. based on radiologic scans within  days of Day  of Cycle 
Have measurable and/or evaluable disease based on RECIST ..
Measurable or evaluable disease by RECIST .
Measurable or evaluable non-measurable disease as assessed by the investigator according to RECIST v. criteria
Evaluable disease as determined by RECIST .
Subjects must have either measurable disease or bone-only non-measurable disease, evaluable according to RECIST .
Evaluable or measurable disease, as assessed by RECIST v.
Radiographically measurable or evaluable disease (per RECIST v.)
. Evaluable disease, or measurable disease as assessed by RECIST version ..
Measurable disease according to RECIST Version . or non-measurable evaluable disease
Evaluable or measurable disease per RECIST v.
Radiologically measurable and clinically evaluable disease as per RECIST v.
Meaurable or evaluable extra-cranial disease as defined by RECIST v .
Evaluable or measurable disease per RECIST v.
Evaluable or measurable disease per RECIST v.
Measurable or evaluable disease by RECIST .
Evaluable or measurable disease per RECIST v.
Evaluable or measurable disease per RECIST v.
Evaluable or measurable disease per RECIST v.
Subject must have evaluable disease as per RECIST criteria.
Measurable disease or non-measurable but evaluable disease, according to the RECIST v.; Participants with peritoneal disease would generally be regarded as having evaluable disease and allowed to enter the trial
Radiographically or clinically evaluable tumor. In the expansion phase, disease must be measurable according to RECIST ..
At least one measurable lesion and/or non-measurable disease evaluable according to RECIST v. criteria
Measurable disease per RECIST . criteria. Subjects with non-measurable, but evaluable disease are also eligible for Part  of the study.
Measurable or evaluable (non-measurable) disease per RECIST guidelines version ..
Measurable disease per RECIST guidelines (subjects with non-measurable, but evaluable disease are also eligible for the dose escalation portion of the study)
Evaluable disease or disease measurable per RECIST
Evaluable or measurable disease per RECIST, Version .
Patient must be evaluable using RECIST . criteria
Evaluable disease or disease measurable per RECIST .
To be enrolled in the dose escalation phase of the study, participants must have a radiographically or clinically evaluable tumor, but measurable disease as defined by RECIST version . [] is not required for participation in this study.